Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management
Authors
Keywords
Cardiovascular complication, Multiple myeloma, Cardiotoxicity, Immunomodulatory drug, Proteasome inhibitor, Relapsed myeloma, Thrombotic complication, Venous thromboembolism, Heart failure, Thromboprophylaxis
Journal
Current Oncology Reports
Volume 21, Issue 4, Pages -
Publisher
Springer Nature
Online
2019-03-05
DOI
10.1007/s11912-019-0784-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
- (2018) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- (2018) Ujjawal H. Gandhi et al. Clinical Lymphoma Myeloma & Leukemia
- Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy
- (2018) Geraldine Ong et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
- (2018) Ajai Chari et al. LEUKEMIA & LYMPHOMA
- Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis
- (2018) Chintan Shah et al. LEUKEMIA & LYMPHOMA
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cardiovascular Complications of Novel Multiple Myeloma Treatments
- (2016) Weijuan Li et al. CIRCULATION
- AL (Light-Chain) Cardiac Amyloidosis
- (2016) Rodney H. Falk et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors
- (2015) Sophia Danhof et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma
- (2015) E. Wilson Grandin et al. JOURNAL OF CARDIAC FAILURE
- Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway
- (2015) Constantine S. Mitsiades JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- (2015) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
- (2015) S Atrash et al. Blood Cancer Journal
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)
- (2014) L. Nayak et al. BLOOD
- Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
- (2014) P. Sonneveld et al. BLOOD
- Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy
- (2014) Paaladinesh Thavendiranathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis
- (2014) Yi Xiao et al. PLoS One
- Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health
- (2014) Matthew I. Tomey et al. Annals of Global Health
- Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma
- (2013) X. Chang et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens
- (2013) Tina Bagratuni et al. AMERICAN JOURNAL OF HEMATOLOGY
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Role of the Ubiquitin Proteasome System in the Heart
- (2013) Julia Pagan et al. CIRCULATION RESEARCH
- Kidney Disease and Multiple Myeloma
- (2013) E. C. Heher et al. Clinical Journal of the American Society of Nephrology
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature
- (2012) Margarita Bockorny et al. ACTA HAEMATOLOGICA
- When a little aspirin may be enough
- (2012) E. Kastritis et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study
- (2012) Rachel Rosovsky et al. BRITISH JOURNAL OF HAEMATOLOGY
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- Thrombosis is associated with inferior survival in multiple myeloma
- (2012) S. Y. Kristinsson et al. HAEMATOLOGICA
- Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
- (2011) A. Larocca et al. BLOOD
- Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens
- (2011) Maurizio Zangari et al. Clinical Lymphoma Myeloma & Leukemia
- Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
- (2011) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
- (2010) S. Y. Kristinsson et al. BLOOD
- High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
- (2010) E. J. Libourel et al. BLOOD
- Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Krüppel-Like Transcription Factors
- (2009) Toyoko Hiroi et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The ubiquitin-proteasome pathway and endothelial (dys)function
- (2009) K. Stangl et al. CARDIOVASCULAR RESEARCH
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
- (2008) S. Y. Kristinsson et al. BLOOD
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
- (2008) Sagar Lonial et al. BRITISH JOURNAL OF HAEMATOLOGY
- A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
- (2008) Lisa K. Hicks et al. CANCER TREATMENT REVIEWS
- Proteasome inhibition promotes regression of left ventricular hypertrophy
- (2007) William E. Stansfield et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Suppression of Cardiomyocyte Hypertrophy by Inhibition of the Ubiquitin-Proteasome System
- (2007) Silke Meiners et al. HYPERTENSION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started